All In Biotech

Drug Trial Radar · NCT06920043

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

42

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Jul 3, 2028

Study completion Jul 3, 2028

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.

Conditions

  • Metabolic Dysfunction-Associated Steatohepatitis
  • Non-alcoholic Fatty Liver Disease

Interventions

  • EfimosferminDrug

    Efimosfermin will be administered as a subcutaneous injection.

  • PlaceboDrug

    Placebo will be administered as a subcutaneous injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events (TEAEs)Time frame: From Day 1 to 100 weeks

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Chandler, Arizona · Recruiting

  • GSK Investigational Site

    Mesa, Arizona · Recruiting

  • GSK Investigational Site

    Tucson, Arizona · Recruiting

  • GSK Investigational Site

    Fresno, California · Recruiting

  • GSK Investigational Site

    Lancaster, California · Recruiting

  • GSK Investigational Site

    Pasadena, California · Recruiting

  • GSK Investigational Site

    Rialto, California · Recruiting

  • GSK Investigational Site

    Santa Maria, California · Recruiting

  • GSK Investigational Site

    Miami, Florida · Recruiting

  • GSK Investigational Site

    Viera, Florida · Recruiting

  • GSK Investigational Site

    Marietta, Georgia · Recruiting

  • GSK Investigational Site

    Baltimore, Maryland · Recruiting

  • GSK Investigational Site

    Kansas City, Missouri · Recruiting

  • GSK Investigational Site

    New York, New York · Recruiting

  • GSK Investigational Site

    Fayetteville, North Carolina · Recruiting

  • GSK Investigational Site

    Wilson, North Carolina · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Austin, Texas · Recruiting

  • GSK Investigational Site

    Dallas, Texas · Recruiting

  • GSK Investigational Site

    Georgetown, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Houston, Texas · Recruiting

  • GSK Investigational Site

    Pasadena, Texas · Recruiting

  • GSK Investigational Site

    Pearland, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    San Antonio, Texas · Recruiting

  • GSK Investigational Site

    Waco, Texas · Recruiting

  • GSK Investigational Site

    Richmond, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.